 WATERTOWN, Mass., Oct. 13, 2021 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated ImmTORTM platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced it will be presenting preclinical data in four posters highlighting its ImmTOR nanoparticle platform and its potential to safely enable repeat vector dosing in gene therapy patients at the 28th Annual Congress of the European Society of Gene Cell Therapy ESGCT taking place virtually from October 19-22, 2021. 